Saturday 17 October 2026
Export ANGO’s income statement to Excel — free account
AngioDynamics, Inc.
ANGO Healthcare Medical Instruments & Supplies
AngioDynamics, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $320.2 million, up 9.46% from fiscal 2025. In the quarter to August 2026, revenue grew 6.87%, EPS grew 35.0% and free cash flow grew 5.62%, each against the same quarter a year earlier.
11.25
0.33
−2.85%
Follow ANGO
| Aug '26 | May '26 | Feb '26 | Nov '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.08 | 1.42 | 1.51 | 1.75 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(44.21) | 25.96 | (151.94) | 115.60 | |
P/B ratio |
4.13 | 2.65 | 2.73 | 3.06 | |
Price to Tangible BV |
6.64 | 4.37 | 4.38 | 4.92 | |
EV/Sales |
2.15 | 1.42 | 1.56 | 1.80 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
190.22 | 146.97 | 110.06 | (98.55) | |
EV/FCF |
(297.81) | (138.33) | (214.05) | (42.07) | |
Quick Ratio |
1.32 | 1.37 | 1.26 | 1.20 | |
Current Ratio |
2.40 | 2.19 | 2.35 | 2.24 | |
Net Debt/EBITDA |
18.83 | 11.71 | 5.14 | 110.15 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.28 | 1.17 | 1.15 | 1.10 | |
Operating CF/Net income |
2.16 | (1.53) | 0.38 | (0.73) | |
Capex/Depreciation |
(0.07) | (0.07) | (0.18) | (0.07) | |
Interest Coverage |
(82.98) | (34.56) | — | — | |
Research and Development Expense of Revenue |
9.86% | 9.44% | 9.03% | 9.78% | |
Selling, General and Administrative Expense of Revenue |
52.47% | 47.79% | 48.65% | 46.41% | |
Intangible Assets out of Total Assets |
0.26 | 0.25 | 0.25 | 0.25 | |
Share Based Compensation of Revenue |
5.56% | 4.52% | 3.42% | 3.64% | |
Graham Net Nets |
0.10 | 0.15 | 0.14 | 0.13 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.83%) | (7.97%) | (6.60%) | (5.17%) | |
Free Cash Flow Yield |
(0.35%) | (0.72%) | (0.48%) | (2.43%) | |
Revenue per Share |
1.93 | 2.09 | 1.89 | 1.91 | |
Operating CF per Share |
(0.36) | 0.42 | (0.07) | 0.11 | |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.01) | |
Free Cash Flow per Share |
(0.37) | 0.41 | (0.10) | 0.10 | |
Cash per Share |
0.81 | 1.30 | 0.91 | 1.00 | |
Shareholders Equity per Share |
3.90 | 4.11 | 4.17 | 4.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.90 | 4.11 | 4.17 | 4.24 | |
Free Cash Flow |
(15.71) | 17.04 | (4.12) | 4.24 | |
Working Capital |
83.31 | 88.68 | 89.49 | 89.39 | |
Capital Expenditures |
(0.38) | (0.41) | (1.01) | (0.42) | |
Net Current Asset Value |
65.03 | 67.06 | 68.23 | 68.00 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
43.77 | 45.61 | 47.26 | 43.80 | |
Average Payables |
29.23 | 32.40 | 29.69 | 35.07 | |
Average Inventory |
58.60 | 57.22 | 60.84 | 65.74 | |
Average Assets |
253.79 | 273.65 | 273.05 | 280.62 | |
Average Common Equity |
171.41 | 176.90 | 179.61 | 181.55 |
Columns are period end dates · fundamentals updated 13 Oct 2026